Request Demo
Last update 20 Mar 2025
ONO-4685
Last update 20 Mar 2025
Overview
Basic Info
Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms |
Target |
Action stimulants, modulators |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), PD-1 modulators(Programmed cell death protein 1 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
6
Clinical Trials associated with ONO-4685JPRN-jRCT2011230051
ONO-4685-05 : An Open-label, Non-randomized, Phase I Dose Escalation Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in Patients With Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL)
NCT06547528
An Open-label, Uncontrolled, Phase I Dose Escalation Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in Patients With Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
JPRN-jRCT2071220081
ONO-4685-04:ONO-4685 Phase 1 study Single intravenous continuous infusion and subcutaneous administration study in Japanese healthy adult male subjects
100 Clinical Results associated with ONO-4685
Login to view more data
100 Translational Medicine associated with ONO-4685
Login to view more data
100 Patents (Medical) associated with ONO-4685
Login to view more data
100 Deals associated with ONO-4685
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Chronic Lymphocytic Leukemia | Phase 1 | Japan | 01 Oct 2023 | |
| Small Lymphocytic Lymphoma | Phase 1 | Japan | 01 Oct 2023 | |
| Plaque psoriasis | Phase 1 | Romania | 25 Mar 2022 | |
| Plaque psoriasis | Phase 1 | Moldova | 25 Mar 2022 | |
| Plaque psoriasis | Phase 1 | United Kingdom | 25 Mar 2022 | |
| T-cell lymphoma recurrent | Phase 1 | United States | 10 Dec 2021 | |
| T-cell lymphoma refractory | Phase 1 | United States | 10 Dec 2021 | |
| Autoimmune Diseases | Phase 1 | European Union | - | |
| Autoimmune Diseases | Phase 1 | Japan | - | |
| Psoriasis | Phase 1 | - | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free